PBLS Stock Forecast: Parabilis Medicines, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Parabilis Medicines, Inc. hold a median 12-month price target of $41 — +20.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
PBLS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Parabilis Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (34): Analysts have, on balance, been raising their forecasts.
Volatility (3): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Parabilis Medicines, Inc. — and when they’d sell — is the membership.
PBLS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PBLS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +20.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 July 2026 | B of A Securities | Initiates | Buy | $45 |
| 6 July 2026 | Guggenheim | Initiates | Buy | $40 |
| 6 July 2026 | Leerink Partners | Initiates | Outperform | $40 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PBLS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Parabilis Medicines, Inc. (PBLS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −18.9×
- Price / sales
- —
- Price / book
- 11.2×
- EV / EBITDA
- −4.2×
Cheaper than 96% of US stocks
Cheaper than 9% of US stocks
Cheaper than 78% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 1131.3%
- Return on assets
- −231.3%
- Dividend yield
- —
Higher than 99% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PBLS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBLS appears on the weeks it earns a place.
Frequently asked questions about PBLS stock
What is the PBLS stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Parabilis Medicines, Inc. have a median 12-month price target of $41, with estimates ranging from $40 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PBLS stock a buy right now?
Of the 5 analysts covering Parabilis Medicines, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Parabilis Medicines, Inc. 1 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PBLS?
As at 1 Aug 2026, Parabilis Medicines, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (34 of 100).
Will PBLS stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +20.7% from the last close, and Ticker Nerd's factor model ranks Parabilis Medicines, Inc. 1 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PBLS stock forecast for 2030?
No analyst covering Parabilis Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBLS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $45 over the next 12 months.
What does Parabilis Medicines, Inc. do?
Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing ultra-tunable peptide therapeutics designed to modulate intracellular proteins that are traditionally difficult to target with conventional medicines.
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing ultra-tunable peptide therapeutics designed to modulate intracellular proteins that are traditionally difficult to target with conventional medicines. Its proprietary Helicon platform combines AI-driven design, high-throughput synthesis, and experimental screening to create stabilized helical peptides for precision drug development. The company’s current pipeline includes investigational programs for serious diseases such as cancer and other complex conditions, with lead efforts centered on zolucatetide, a direct inhibitor of the β-catenin:TCF interaction in the Wnt/β-catenin pathway. Parabilis Medicines also advances additional programs in targeted protein degradation and other intracellular mechanisms, reflecting its role in expanding the therapeutic reach of peptide-based medicines across oncology and related disease areas.
CEO Dr. Mathai Mammen M.D., Ph.D. · 145 employees · United States · https://parabilismed.com